SCHEMBL6565313

SCHEMBL6565313

CCOC(=O)CC(=O)COCc1ccc(CC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
GAA P10253 2/20 0.42
MGAM O43451 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
CSNK1D P48730 1/20 0.40
TSHR P16473 1/20 0.40
NLRP3 Q96P20 1/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
NAAA Q02083 1/20 0.38
PLA2G4B P0C869 1/20 0.38
PLK1 P53350 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6567531 0.91 GAA (0.48) ALDH1A1GAAMGAMSIMGAM2
SCHEMBL53331 0.88 PPID (0.49) ALDH1A1GAAMGAMSIMGAM2
SCHEMBL7231280 0.87 ALDH1A1 (0.45) ALDH1A1TDP1GAACYP4F2CYP4A11
SCHEMBL130309 0.87 KMT2A (0.49) ALDH1A1MAPTPLA2G4B
SCHEMBL2042795 0.85 PPID (0.47) ALDH1A1GAACSNK1DHSD17B10MAPT
SCHEMBL6568585 0.82 RXRA (0.45) ALDH1A1TDP1GAAHRH3CSNK1D
SCHEMBL12290360 0.81 GAA (0.51) ALDH1A1GAARXRARXRBPLA2G4B
SCHEMBL3230548 0.80 LMNA (0.47) ALDH1A1KDM4ECA12CA1CA2
SCHEMBL13967502 0.78 ALDH1A1 (0.49) ALDH1A1TDP1GAACYP4F2CYP4A11
SCHEMBL6568404 0.78 RAB9A (0.49) ALDH1A1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1277748-B1 Process for producing optically active y-Butyrolactone TAKASAGO PERFUMERY CO LTD (JP) 2004-04-21 EP disclosed
EP-1403262-A1 Process for producing optically active alpha butyrolactone Takasago International Corporation (JP) 2004-03-31 EP disclosed
US-6608214-B2 Hydrogenating optically active 4-substituted oxy-3-hydroxy-butyrate followed by simultaneous deprotection and ring closure; economic and efficient synthesis TAKASAGO INTERNATIONAL CORPORATION (JP) 2003-08-19 US disclosed
US-20030105341-A1 Process for producing optically active gamma-butyrolactone TAKASAGO INTERNATIONAL CORPORATION (JP) 2003-06-05 US disclosed
EP-1277748-A1 Process for producing optically active y-Butyrolactone Takasago International Corporation (JP) 2003-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105341-A1 Process for producing optically active gamma-butyrolactone HSD17B10, HSD17B1, HSD17B12 ALDH1A1 77/4885TDP1 3673/4885GAA 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.